BEAM-302 Achieves Key Milestone: 94% Corrected Protein and 84% Mutant Reduction Mark Pivotal Progress in AATD Trial
Market Chameleon (Wed, 25-Mar 7:32 AM)
Beam Therapeutics Expands Genetic Disease Pipeline and Extends Cash Runway with New Strategic Initiatives
Market Chameleon (Tue, 24-Feb 8:43 AM)
